Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Acta Psychiatr Scand. 2008 Nov;118(5):347-56. doi: 10.1111/j.1600-0447.2008.01257.x. Epub 2008 Aug 24.

Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks.

Author information

  • 1Mood Disorders Program, Department of Psychiatry, Tufts Medical Center, Boston, MA 02111, USA. nghaemi@tuftsmedicalcenter.org

Abstract

OBJECTIVE:

Long-term antidepressant (AD) treatment for depression in bipolar disorder (BPD) patients is highly prevalent, but its benefits and risks remain uncertain, encouraging this meta-analysis of available research.

METHOD:

We reviewed randomized controlled trials for BPD involving >or=6 months of treatment with AD +/- mood stabilizer (MS) vs. placebo +/- MS, using meta-analyses to compare reported risks of new depression vs. mania.

RESULTS:

In seven trials (350 BPD patients) involving 12 contrasts, long-term treatments that included ADs yielded 27% lower risk of new depression vs. MS-only or no treatment [pooled relative risk, RR = 0.73; 95% CI 0.55-0.97; number-needed-to-treat (NNT) = 11], but 72% greater risk for new mania [RR = 1.72; 95% CI 1.23-2.41; number-needed-to-harm (NNH) = 7]. Compared with giving an MS-alone, adding an AD yielded neither major protection from depression (RR = 0.84; 95% CI 0.56-1.27; NNT = 16) nor substantial increase in risk of mania (RR = 1.37; 95% CI 0.81-2.33; NNH = 16).

CONCLUSION:

Long-term adjunctive AD treatment was not superior to MS-alone in BPD, further encouraging reliance on MSs as the cornerstone of prophylaxis.

Comment in

PMID:
18727689
[PubMed - indexed for MEDLINE]
PMCID:
PMC2718794
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central Icon for PubMed Central Icon for PubMed Health
    Loading ...
    Write to the Help Desk